Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ying, Hejazi, Nima S., Blette, Bryan, Carpp, Lindsay N., Benkeser, David, Montefiori, David C., McDermott, Adrian B., Fong, Youyi, Janes, Holly E., Deng, Weiping, Zhou, Honghong, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Flach, Britta, Lin, Bob C., O’Connell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, Kenny, Avi, Carone, Marco, Huynh, Chuong, Miller, Jacqueline, El Sahly, Hana M., Baden, Lindsey R., Jackson, Lisa A., Campbell, Thomas B., Clark, Jesse, Andrasik, Michele P., Kublin, James G., Corey, Lawrence, Neuzil, Kathleen M., Pajon, Rolando, Follmann, Dean, Donis, Ruben O., Koup, Richard A., Gilbert, Peter B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612023/
https://www.ncbi.nlm.nih.gov/pubmed/37896806
http://dx.doi.org/10.3390/v15102029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612023/
https://www.ncbi.nlm.nih.gov/pubmed/37896806
http://dx.doi.org/10.3390/v15102029

Ejemplares similares